Posted by Michael Wonder on 06 Sep 2023
'Joint reimbursement of Opdivo, CDx platform marks milestone in gastric cancer but challenges remain'
6 September 2023 - Oncology experts celebrated the joint reimbursement of Opdivo together with its PD-L1 IHC 28-8 PharmDx companion diagnostic platform for first-line treatment and diagnosis of advanced and metastatic gastric cancer in Korea.
However, they noted diagnosis platforms need work to improve treatment access for eligible patients.
